These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

307 related items for PubMed ID: 22024513

  • 1. Pegylated interferon-α monotherapy leads to low response rates in HIV-infected patients with acute hepatitis C.
    Arends JE, van Assen S, Stek CJ, Wensing AM, Fransen JH, Schellens IM, Spijkers SN, Mudrikova T, van Baarle D, Sprenger HG, Hoepelman AI.
    Antivir Ther; 2011; 16(7):979-88. PubMed ID: 22024513
    [Abstract] [Full Text] [Related]

  • 2. IL28B polymorphism genotyping as predictor of rapid virologic response during interferon plus ribavirin treatment in hepatitis C virus genotype 1 patients.
    Rosso C, Abate ML, Ciancio A, Strona S, Caviglia GP, Olivero A, Touscoz GA, Rizzetto M, Pellicano R, Smedile A.
    World J Gastroenterol; 2014 Sep 28; 20(36):13146-52. PubMed ID: 25278709
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Boceprevir plus pegylated interferon/ribavirin to re-treat hepatitis C virus genotype 1 in HIV-HCV co-infected patients: final results of the Spanish BOC HIV-HCV Study.
    Laguno M, Von Wichmann MA, Van den Eynde E, Navarro J, Cifuentes C, Murillas J, Veloso S, Martínez-Rebollar M, Guardiola JM, Jou A, Gómez-Sirvent JL, Cervantes M, Pineda JA, López-Calvo S, Carrero A, Montes ML, Deig E, Tapiz A, Ruiz-Mesa JD, Cruceta A, de Lazzari E, Mallolas J.
    Int J Infect Dis; 2016 Dec 28; 53():46-51. PubMed ID: 27815225
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Lead-in treatment with interferon-β/ribavirin may modify the early hepatitis C virus dynamics in pegylated interferon alpha-2b/ribavirin combination for chronic hepatitis C patients with the IL28B minor genotype.
    Itokawa N, Atsukawa M, Tsubota A, Kondo C, Hashimoto S, Fukuda T, Matsushita Y, Kidokoro H, Kobayashi T, Narahara Y, Nakatsuka K, Kanazawa H, Iwakiri K, Sakamoto C.
    J Gastroenterol Hepatol; 2013 Mar 28; 28(3):443-9. PubMed ID: 23173698
    [Abstract] [Full Text] [Related]

  • 9. Sustained virological response after 14-day treatment with danoprevir and 48-week treatment with pegylated interferon-α2a (40 KD) plus ribavirin.
    Larrey D, Carenco C, Guyader D, Boyer N, Benhamou Y, Pageaux GP, Rouzier R, Marcellin P.
    Antivir Ther; 2012 Mar 28; 17(5):927-32. PubMed ID: 22611092
    [Abstract] [Full Text] [Related]

  • 10. Long-term pegylated interferon monotherapy following 72 weeks of pegylated interferon and ribavirin in hepatitis C virus genotype-1-infected slow responders.
    Watanabe S, Kobayashi Y, Kawata K, Noritake H, Chida T, Nagasawa M, Kageyama F, Kawamura K, Sasada Y, Suda T.
    Intern Med; 2015 Mar 28; 54(3):273-9. PubMed ID: 25748735
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Strong prediction of virological response to combination therapy by IL28B gene variants rs12979860 and rs8099917 in chronic hepatitis C genotype 4.
    Ragheb MM, Nemr NA, Kishk RM, Mandour MF, Abdou MM, Matsuura K, Watanabe T, Tanaka Y.
    Liver Int; 2014 Jul 28; 34(6):890-5. PubMed ID: 24102823
    [Abstract] [Full Text] [Related]

  • 16. OPERA: responses to peginterferon and ribavirin therapy in a subgroup of interferon-naïve patients with HIV/HCV genotype 2/3 co-infection in Italy.
    Bruno R, Cariti G, Nasta P, Capetti A, Ravasio V, Galli M, Raise E, Palmieri G, Iannacone C, Puoti M.
    Liver Int; 2015 Jan 28; 35(1):120-9. PubMed ID: 25041136
    [Abstract] [Full Text] [Related]

  • 17. Distinct hepatitis C virus kinetics in HIV-infected patients treated with ribavirin plus either pegylated interferon alpha2a or alpha2b.
    Vispo E, Barreiro P, Rodriguez-Nóvoa S, Morello J, Labarga P, Martín-Carbonero L, Maida I, García-Gascó P, Soriano V.
    Antivir Ther; 2008 Jan 28; 13(4):511-7. PubMed ID: 18672529
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Differences in virological response to pegylated interferon and ribavirin between hepatitis C virus (HCV)-monoinfected and HCV-HIV-coinfected patients.
    Tural C, Galeras JA, Planas R, Coll S, Sirera G, Giménez D, Salas A, Rey-Joly C, Cirera I, Márquez C, Tor J, Videla S, García-Retortillo M, Clotet B, Solà R.
    Antivir Ther; 2008 Jan 28; 13(8):1047-55. PubMed ID: 19195330
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.